Chinese vaccine developer reaches Phase 3 testing
A Chinese vaccine developer took the lead in the biotech "Space Race" to develop the world's first Covid-19 vaccine.
Sinopharm's subsidiary, China National Biotec Group (CNBG), kicked off a Phase 3 trial for one of its novel coronavirus vaccine candidates after getting permission to conduct the study in the United Arab Emirates.
The state-backed biotech will be working with Group 42, an Abu Dhabi-based artificial intelligence and cloud computing company, to conduct the clinical trial and manage local production.
The vaccine they are testing contains an inactivated version of the novel coronavirus. It was first developed by CNBG's subsidiary, the Wuhan Institute of Biological Products, which led the program through its Phase 1 and 2 development.
Sinopharm Group has been accelerating its Covid-19 development programs. Since April, the company has been building the country's first and only world class-level vaccine manufacturing facility. Once fully functional, its vaccine production can scale up to more than 200 million doses per year.
Sinopharm's subsidiary, China National Biotec Group (CNBG), kicked off a Phase 3 trial for one of its novel coronavirus vaccine candidates after getting permission to conduct the study in the United Arab Emirates.
The state-backed biotech will be working with Group 42, an Abu Dhabi-based artificial intelligence and cloud computing company, to conduct the clinical trial and manage local production.
The vaccine they are testing contains an inactivated version of the novel coronavirus. It was first developed by CNBG's subsidiary, the Wuhan Institute of Biological Products, which led the program through its Phase 1 and 2 development.
Sinopharm Group has been accelerating its Covid-19 development programs. Since April, the company has been building the country's first and only world class-level vaccine manufacturing facility. Once fully functional, its vaccine production can scale up to more than 200 million doses per year.
.png)
No hay comentarios:
Publicar un comentario